Zai Lab (ZLAB) Revenue & Revenue Breakdown
Zai Lab Revenue Highlights
Latest Revenue (Y)
$266.72M
Latest Revenue (Q)
$100.50M
Main Segment (Y)
Zejula
Zai Lab Revenue by Period
Zai Lab Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $266.72M | 24.03% |
| 2022-12-31 | $215.04M | 49.01% |
| 2021-12-31 | $144.31M | 194.77% |
| 2020-12-31 | $48.96M | 277.04% |
| 2019-12-31 | $12.98M | 9930.55% |
| 2018-12-31 | $129.45K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Zai Lab generated $266.72M in revenue during NA 2023, up 24.03% compared to the previous quarter, and up 206036.99% compared to the same period a year ago.
Zai Lab Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $100.50M | 15.32% |
| 2024-03-31 | $87.15M | 32.38% |
| 2023-12-31 | $65.83M | -4.91% |
| 2023-09-30 | $69.23M | 0.53% |
| 2023-06-30 | $68.86M | 9.66% |
| 2023-03-31 | $62.80M | 0.31% |
| 2022-12-31 | $62.60M | 8.80% |
| 2022-09-30 | $57.54M | 19.44% |
| 2022-06-30 | $48.18M | 3.11% |
| 2022-03-31 | $46.72M | 5.78% |
| 2021-12-31 | $44.17M | 2.48% |
| 2021-09-30 | $43.10M | 16.70% |
| 2021-06-30 | $36.94M | 83.73% |
| 2021-03-31 | $20.10M | 33.19% |
| 2020-12-31 | $15.09M | 3.02% |
| 2020-09-30 | $14.65M | 33.25% |
| 2020-06-30 | $10.99M | 33.79% |
| 2020-03-31 | $8.22M | 76.92% |
| 2019-12-31 | $4.65M | -5.58% |
| 2019-09-30 | $4.92M | 187.69% |
| 2019-06-30 | $1.71M | - |
| 2019-03-31 | $1.71M | 1220.95% |
| 2018-12-31 | $129.45K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | - |
Zai Lab generated $100.50M in revenue during Q2 2024, up 15.32% compared to the previous quarter, and up 160.05% compared to the same period a year ago.
Zai Lab Revenue Breakdown
Zai Lab Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Qinlock | $19.24M | $14.96M | $11.62M | - |
| Zejula | $168.84M | $145.19M | $93.58M | $32.14M |
| Nuzyra | $21.66M | $5.20M | $3.00K | - |
| Optune | $46.97M | $47.32M | $38.90M | $16.42M |
| Other | - | - | - | $402.00K |
Zai Lab's latest annual revenue breakdown by segment (product or service), as of Dec 23: Zejula (65.77%), Optune (18.30%), Nuzyra (8.44%), and Qinlock (7.49%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuzyra | $9.91M | $6.07M | $5.48M | $4.64M | $5.47M | $1.60M | $1.55M | $1.31M | $742.00K | - | - | - | - | - |
| Zejula | $45.50M | $41.61M | $41.59M | $42.96M | $42.68M | $42.33M | $39.21M | $34.05M | $29.60M | $29.45M | $28.16M | $23.37M | $12.61M | $13.79M |
| Qinlock | $6.09M | $4.71M | $5.70M | $7.53M | $1.31M | $5.83M | $5.54M | $623.00K | $2.96M | $2.93M | $4.29M | $4.03K | - | - |
| Optune | $12.48M | $8.37M | $11.56M | $13.69M | $13.34M | $12.27M | $10.66M | $11.59M | $12.80M | $11.59M | $10.65M | $9.54M | $7.13M | $5.42M |
| Other | - | - | - | - | - | - | - | - | - | - | - | - | $367.00K | - |
Zai Lab's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Zejula (61.50%), Optune (16.87%), Nuzyra (13.40%), and Qinlock (8.24%).
Zai Lab Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ZLAB | Zai Lab | $266.72M | $100.50M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| ROIV | Roivant Sciences | $124.80M | $55.13M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| RXDX | Prometheus Biosciences | $6.81M | $1.10M |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| ERAS | Erasca | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
ZLAB Revenue FAQ
What is Zai Lab’s yearly revenue?
Zai Lab's yearly revenue for 2023 was $266.72M, representing an increase of 24.03% compared to 2022. The company's yearly revenue for 2022 was $215.04M, representing an increase of 49.01% compared to 2021. ZLAB's yearly revenue for 2021 was $144.31M, representing an increase of 194.77% compared to 2020.
What is Zai Lab’s quarterly revenue?
Zai Lab's quarterly revenue for Q2 2024 was $100.5M, a 15.32% increase from the previous quarter (Q1 2024), and a 45.95% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $87.15M, a 32.38% increase from the previous quarter (Q4 2023), and a 38.78% increase year-over-year (Q1 2023). ZLAB's quarterly revenue for Q4 2023 was $65.83M, a -4.91% decrease from the previous quarter (Q3 2023), and a 5.16% increase year-over-year (Q4 2022).
What is Zai Lab’s revenue growth rate?
Zai Lab's revenue growth rate for the last 3 years (2021-2023) was 84.82%, and for the last 5 years (2019-2023) was 1954.09%.
What are Zai Lab’s revenue streams?
Zai Lab's revenue streams in c 23 are Qinlock, Zejula, Nuzyra, and Optune. Qinlock generated $19.24M in revenue, accounting 7.49% of the company's total revenue, up 28.64% year-over-year. Zejula generated $168.84M in revenue, accounting 65.77% of the company's total revenue, up 16.29% year-over-year. Nuzyra generated $21.66M in revenue, accounting 8.44% of the company's total revenue, up 316.46% year-over-year. Optune generated $46.97M in revenue, accounting 18.30% of the company's total revenue, down -0.74% year-over-year.
What is Zai Lab’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Zai Lab was Zejula. This segment made a revenue of $168.84M, representing 65.77% of the company's total revenue.